ArticleScientific reports2026
Mechanism of isoleucyl-tRNA synthetase 2 regulating proliferation and apoptosis of cervical cancer cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Isoleucyl-tRNA synthetase 2 (IARS2) is a mitochondrial isoleucine-tRNA synthetase of the class I aminoacyl-tRNA synthetase family, and its role in cervical cancer remains poorly defined. Here, we report that IARS2 promotes cervical cancer cell proliferation and survival through regulation of the Rag GTPases and mTORC1. Elevated IARS2 expression was associated with poorer overall survival in patients with cervical cancer. Silencing of IARS2 significantly reduced cell viability and induced apoptosis in cervical cancer cells. Mechanistically, IARS2 inhibited mTOR degradation and sustained activation of the mTOR–eIF4E axis, thereby supporting cell proliferation. The amino acid–binding pocket of IARS2 was essential for these regulatory effects. Moreover, immunoprecipitation assays revealed that IARS2 interacted with Rag GTPases, particularly RagB and RagD. Together, these findings suggest that IARS2 may function as an amino acid sensor within the Rag–mTORC1 complex and highlight IARS2 as a potential therapeutic target in cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.